Format

Send to

Choose Destination
See comment in PubMed Commons below
Clin Pharmacol Ther. 2010 Nov;88(5):712-9. doi: 10.1038/clpt.2010.130. Epub 2010 Jul 28.

Recognition and management of significant drug interactions in HIV patients: challenges in using available data to guide therapy.

Author information

1
Division of Clinical Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA. apau@niaid.nih.gov

Abstract

Combination antiretroviral therapy (cART) has improved survival rates in HIV-infected patients; however, patients now experience comorbidities that require pharmacological intervention, thereby increasing the risk of drug-drug interactions (DDIs). HIV protease inhibitors (PIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), and the CCR5 antagonist maraviroc are primarily metabolized via the cytochrome P450 (CYP) system and are prone to pharmacokinetic interactions.(1,2) This article addresses some key challenges that prescribers face when using available drug interaction-data resources in making day-to-day clinical decisions.

PMID:
20668439
PMCID:
PMC2995199
DOI:
10.1038/clpt.2010.130
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Wiley Icon for PubMed Central
    Loading ...
    Support Center